These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28031737)

  • 1. HDR and LDR Brachytherapy in the Treatment of Lip Cancer: the Experience of the Catalan Institute of Oncology.
    Ayerra AQ; Mena EP; Fabregas JP; Miguelez CG; Guedea F
    J Contemp Brachytherapy; 2010 Mar; 2(1):9-13. PubMed ID: 28031737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
    Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
    Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose-rate versus low dose-rate brachytherapy for lip cancer.
    Ghadjar P; Bojaxhiu B; Simcock M; Terribilini D; Isaak B; Gut P; Wolfensberger P; Brömme JO; Geretschläger A; Behrensmeier F; Pica A; Aebersold DM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1205-12. PubMed ID: 22099044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
    Petereit DG; Sarkaria JN; Potter DM; Schink JC
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
    Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
    Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment.
    Cuenin M; Salleron J; Peiffert D; Meknaci É; Gallet P; Abushama Y; Py JF; Renard S
    Cancer Radiother; 2024 Apr; 28(2):145-151. PubMed ID: 38072744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.
    Romano KD; Pugh KJ; Trifiletti DM; Libby B; Showalter TN
    Brachytherapy; 2017; 16(2):378-386. PubMed ID: 28139420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer.
    Kucera H; Pötter R; Knocke TH; Baldass M; Kucera E
    Wien Klin Wochenschr; 2001 Jan; 113(1-2):58-62. PubMed ID: 11233470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers.
    Varela Cagetti L; Zemmour C; Salem N; Minsat M; Ferrè M; Mailleux H; Giovaninni M; Lelong B; De Chaisemartin C; Ries P; Poizat F; Tallet A; Moureau-Zabotto L
    Brachytherapy; 2019; 18(6):814-822. PubMed ID: 31515067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer.
    Resch A; Pötter R; Van Limbergen E; Biber E; Klein T; Fellner C; Handl-Zeller L; Langbauer G; Schürer-Waldheim H; Staffen A; Jakesz R; Kubista E; Lehr S; Seitz W
    Radiother Oncol; 2002 Apr; 63(1):47-58. PubMed ID: 12065103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
    Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
    Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate brachytherapy at 3 Gy per fraction for lip carcinoma: Treatment outcomes and toxicity at 5-years.
    Tuček L; Sirák I; Hodek M; Kašaová L; Grepl J; Paluska P; Pohanková D; Hruška L; Vošmik M; Petera J
    Brachytherapy; 2023; 22(4):496-502. PubMed ID: 37015847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.